Janux Therapeutics, Inc. (JANX) Net earnings per share growth forecast for next year

Symbol and logo of brand Janux Pharma (JANX)

Janux Therapeutics (JANX) is currently burning capital on clinical trials without stable revenue, which is reflected in the price action. The valuation of forward net income growth rates demonstrates the market reaction, where the metric value stands at -55.50. The brand possesses high scientific credibility in immuno-oncology, while sufficient liquidity reserves and the success of T-cell platforms provide the company with access to new investments.

JANX - Janux Pharma Earnings growth forecast for next year over the range 07/04/2022 - 11/17/2026

Metric breakdowns and analytics for Janux Pharma (JANX)

- price and consensus price forecast:
Analysis of all company metrics:Janux Pharma
Core merchandise of Janux Therapeutics Inc

Janux Therapeutics (JANX) is scaling the development of T-cell activators through bioscreening robotization and AI modeling, radically reducing costs associated with routine laboratory labor. By analyzing the target EPS growth rates for the coming year, the investor observes aggregated institutional demand and projected profit dynamics, which allows for the identification of valuation gaps and the determination of the stability of current quotes relative to the fundamental quality of the business.

Direct competitors

Net earnings per share growth forecast for next year immunitybio.com|Expected earnings per share growth for next year immunocore.com (IMCR)|Net earnings per share growth forecast for next year Arcus Biosciences Inc (RCUS)|Expected earnings per share growth for next year Zymeworks Corp ZYME|Tango Therapeutics Inc - Expected earnings per share growth for next year|Earnings growth forecast for next year Iovance Corp IOVA|IMTX - Net earnings per share growth forecast for next year|XNCR (xencor.com) - Projected earnings per share growth rate for next year|Compass Therapeutics Corp (CMPX) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Replimune Corp (REPL)|Expected earnings per share growth for next year LYEL|IPHA - Net earnings per one share growth forecast for next year|Expected earnings per share growth for next year PYXS (Pyxis Oncology, Inc.)|Projected earnings per share increase next year CGEN|Earnings growth forecast for next year IOBT (IO Biotech)|Expected earnings per share trend next year STRO|minktherapeutics.com - Earnings growth forecast for next year|Expected net earnings per share growth next year Werewolf Therapeutics, Inc.|Immix (IMMX) - Net earnings per share growth forecast for next year|ALX Oncology Holdings - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Cue Biopharma|Earnings growth forecast for next year pdsbiotech.com|Net earnings per share growth forecast for next year sonnetbio.com (SONN)|MAIA: Net earnings per share change forecast for next year|Liminatus Pharma Inc. - Expected earnings per share growth for next year|LAVA Therapeutics N.V. (LVTX) - Expected net earnings per share growth next year|NXTC - Net earnings per share growth forecast for next year|LPTX: Net earnings per share growth forecast for next year|Intensity Therapeutics (INTS) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Sensei Bio (SNSE)|TOVX (Theriva Biologics Inc) - Earnings growth forecast for next year|Gritstone bio (GRTS) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year KA|Consensus forecast of earnings per share growth for next year NexImmune Inc|Net earnings per share growth forecast for next year turnstonebio.com TSBX|Consensus forecast of earnings per share growth for next year Vaccinex Inc (VCNX)|HARP - Net earnings per share growth forecast for next year